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In healthy individuals, influenza causes
self-limited disease. An appropriate im-
mune response leads to a rapid viral clear-
ance, thereby limiting the duration of viral
shedding to !10 days in most adults. In
contrast, subjects with an impaired im-
mune response might not efficiently clear
influenza infection, thereby leading to ad-
ditional replication cycles and higher viral
loads. In these circumstances, given the
intrinsic abilities of this RNA virus to ac-
cumulate point mutations, the likelihood
of the emergence of new quasi species in-
creases rapidly. According to the resulting
phenotypic changes, new emerging mu-
tants can escape the different environ-
mental constraints (antigenic drift), in-
cluding the host’s immune responses and
drug pressures. At an individual level, such
adapted viruses may contribute to viral
persistence and decrease the efficacy of an-
tiviral drugs. On a wider level, new drifted
strains lead to vaccine escape and could
promote progressive adaptation of animal
strains to humans.
In this issue, Baz et al. [1] describe a
stem cell transplant recipient presenting
with a chronic influenza infection for
months. This careful study described a
case in which oral oseltamivir that was
administered for weeks failed to clear the
influenza infection, and resistant clones
emerged. By sequencing several clones, the
authors showed that isolates harboring re-
sistance to neuraminidase inhibitors
(mainly the E119V mutation on the neu-
raminidase gene) and amantadine (mainly
the S31N mutation on the M2 gene) rap-
idly became dominant. Moreover, clones
carrying both neuraminidase and M2-
resistance mutations were detected. Al-
though it is known that M2-resistant vi-
ruses can easily be selected, persist, and be
transmitted, neuraminidase resistance was
considered until very recently to be un-
common and associated with decreased
fitness [2, 3]. However, in addition to the
article by Baz et al. [1], similar reports of
infection in immunocompromised pa-
tients [4, 5] and observations in children
and recent cases of influenza A/H5N1
have tempered this relatively optimistic
view. In hospitalized children receving os-
eltamivir, a resistance rate of 18% has been
documented [6], and in patients treated
for H5N1 avian influenza, resistant clones
have rapidly emerged [7, 8]. Is there a
common key point that could promote
influenza resistance in immunocomprom-
ised hosts, in children with an acute pri-
mary infection, and in human cases of
H5N1 avian influenza? This is possibly the
combination of a delayed or failing im-
mune response with a protracted infection
and high viral loads. Given the intrinsic
abilities of influenza to mutate or even to
recombine, this is an invitation to select
new mutants while exposed to drugs, par-
ticularly if drug levels are suboptimal. In
the study by Baz et al. [1], oseltamivir se-
lected a complex pattern of mutations on
the neuraminidase gene that could com-
bine and accumulate to increase resistance
step-by-step or in a synergistic manner.
The identification of concomitant muta-
tions on the hemagglutinin gene also
needs to be highlighted, because these mu-
tations could possibly restore viral fitness
[9] and also contribute to the transmis-
sibility of multidrug-resistant viral quasi
species. At this time and to the best of our
knowledge, transmission of oseltamivir-
resistant H3N2 influenza virus in humans
has not been observed [10], but this seems
just a question of time. In a ferret model,
resistant H3N2 influenza virus carrying
the E119V mutations has already proved
to be transmissible [11]. In humans, a re-
cent investigation suggests strongly that
H5N1 influenza virus clones have been
transmitted from brother to sister [8]. In
the study by Baz et al. [1], multidrug-
resistant virions were isolated even after
cessation first of oseltamivir and then of
amantadine—a definitive confirmation
that these viruses can survive in immu-
nocompromised hosts [4, 5]. It would be
naive to consider oseltamivir-resistant or
multidrug-resistant influenza viruses as
uniformly unfit and nontransmissible.
From a clinical point of view, the study
by Baz et al. [1] well complements pre-
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vious similar observations in immuno-
compromised patients [4, 5] and raises at
least 4 important questions for clinicians
caring for immunocompromised hosts:
(1) What is the frequency of influenza in-
fections in immunocompromised hosts
and what is the relative importance of in-
fluenza compared with other respiratory
viruses that are circulating in the com-
munity? Although every immunocom-
promised subject is at risk for influenza
during seasonal outbreaks (the severity of
which can vary from year to year), influ-
enza seems not to be the most frequent
respiratory virus affecting these subjects.
The so-called common-cold viruses (rhi-
novirus and coronavirus), which are often
not routinely detected, present similar
clinical illnesses but are epidemiologically
much more frequently present [12]. Thus,
the real impact of respiratory virus as a
whole (and not only influenza virus) needs
to be better appreciated. (2) In the case of
influenza infection, how often do severe
complications occur? Many reports have
shown that influenza can be relatively in-
dolent in immunocompromised hosts
[13], but could also lead to severe lower
respiratory tract events [14]. The rate of
influenza-related complications (e.g., viral
pneumonia, bacterial or fungal compli-
cations, or graft rejection) needs to be sys-
tematically investigated. (3) Oseltamivir
and other neuraminidase inhibitors are ef-
fective in healthy adults and adolescents
and, to some extent, decrease the rate of
complications leading to antibiotic pre-
scriptions [3, 15]. Studies have suggested
that neuraminidase inhibitors are also
effective in the elderly and those with
chronic lung diseases, but these drugs have
never been evaluated systematically in
hospitalized subjects or in immunocom-
promised hosts. Whether the expected
benefit would be significant in these pop-
ulations remains to be proven. (4) The
usual oseltamivir or zanamivir regimens
have been established and standardized
again for healthy adults. Is there a dose-
response relationship and should the
dosage and the duration be increased in
immunocompromised hosts as recom-
mended by some experts? Could this pre-
vent emergence of resistance? Is there an
advantage to prescribe combination ther-
apy, as was done in the present case? Com-
bination therapy is an attractive concept
and has been tested in a limited number
of hospitalized subjects, with inconclusive
results [16]. These issues also illustrate the
need for new antiviral drugs and therapy
that are efficiently distributed in the re-
spiratory tract.
Good news confirmed by the present
report is that cross-resistance between
neuraminidase inhibitors is not the rule
and that oseltamivir-resistant clones were
still susceptible to zanamivir or other neu-
raminidase inhibitors in development.
Less-good news is that amantadine resis-
tance has been identified in up to 92% of
influenza isolates recently surveyed in the
United States, where amantadine and ri-
mantadine are used for community-
acquired influenza virus infection [17].
This is a dramatic increase compared with
previous years and reveals that resistant
strains can dominate a continent and rap-
idly spread worldwide. Amantadine-resis-
tant avian influenza is also a common
finding in animals [18]. Keeping in mind
that millions of dollars have been spent to
stockpile oseltamivir, the study by Baz et
al. [1] emphasizes the need for investigation
to assess the risk of neuraminidase inhibitor
resistance where it matters the most—in hos-
pitalized patients, immunocompromised
hosts, persons with chronic lung diseases,
young children, and, of course, in cases of
avian influenza. As a first step, spending
money to stockpile oseltamivir against
H5N1 influenza is a wise move, but this
should be complemented by significant
support for clinical investigations in at-
risk populations that provide the virus
with an ideal setting for adaptation. Oth-
erwise, empirical strategies and expert
opinions will remain the rule for the fu-
ture. Influenza will not miss opportuni-
ties to resist therapy—whether case-by-
case in immunocompromised hosts or
on a larger scale by spreading in the com-
munity—and why not in a pandemic
fashion?
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